← 홈

ADC

176개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 176개
ADCAFDAFDABiologicstaleAbbViePhase 3

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Advanced Solid Tumors Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase3#FDA승인#항체약물접합체+3
효능 ORR 33.3%임상시험 12상태 RECRUITING
ADCBHotBiologicAcademic and Community Cancer R…Phase 3

Lenvatinib (Lenvatinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · Solid Tumor

#SolidTumor#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 70.3%임상시험 164상태 RECRUITING
ADCSHotBiologicNovartis PharmaceuticalsApproved

Prednisolone (Prednisolone)

Healthy · Solid Tumor

#SolidTumor#ADC#Approved#인기#항체약물접합체+3
효능 ORR 85.5%임상시험 132상태 RECRUITING
ADCBHotBiologicstaleDaiichi SankyoPhase 1

DP (DS-8201a, DS-8201a (DP))

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#인기#항체약물접합체+2
효능 ORR 69.7%임상시험 107상태 ACTIVE
ADCCBiologicstaleEMD SeronoSN-38 for the treatment of …Phase 2

TMZ (Temozolomide, Temozolomide (TMZ))

Childhood Cancer; Childhood Solid Tumor · Advanced Solid Malignancies

#AdvancedSolidMalignancies#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 40%임상시험 97상태 RECRUITING
ADCCBiologicstaleNovartis PharmaceuticalsdeliveryPhase 3

Trametinib (Trametinib)

KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 100%임상시험 79상태 DISCONTINUED
ADCBBiologicstaleAmgensPhase 3

Sunitinib (Sunitinib)

Advanced Solid Tumors · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 78%임상시험 76상태 RECRUITING
ADCBiologicstaleHansoh BioMedical R&D Companyvedotin with pembrolizumabPhase 3

Cisplatin / carboplatin (Cisplatin / carboplatin)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 84%임상시험 67상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCvedotin combined with pembr…Phase 2

Immune Checkpoint Inhibitor (Immune Checkpoint Inhibitor)

Unspecified Adult Solid Tumor, Protocol Specific · Gastric Cancer

#GastricCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 59%임상시험 66상태 RECRUITING
ADCBiologicstaleNovartis PharmaceuticalsPhase 2

Ribociclib (Ribociclib)

KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung · Breast Cancer

#BreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 66.7%임상시험 66상태 RECRUITING
ADCBiologicstaleDaiichi SankyoDM1) and trastuzumab deruxt…Phase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Breast Cancer; HER2-positive Breast Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 65.8%임상시험 66상태 RECRUITING
ADCBiologicstaleDaiichi SankyoreleasePhase 1

DP1 (DS-8201a, DS-8201a (DP1))

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#인기#항체약물접합체+4
효능 ORR 79.7%임상시험 64상태 ACTIVE
ADCBiologicBioNTech SEPhase 2

Paroxetine (Paroxetine)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#인기#항체약물접합체+2
임상시험 60상태 RECRUITING
ADCBiologicAscendis Pharma Endocrinology D…Preclinical

Targeted drugs (Targeted drugs)

Immune-related Adverse Event; Malignant Solid Tumors · Immune-related Adverse Event

#Immune-relatedAdverseEvent#ADC#Preclinical#인기#항체약물접합체+4
효능 ORR 15%임상시험 60상태 RECRUITING
ADCBiologicAtreca, Inc.vedotin (BV), an anti-CD30 …Preclinical

PD-1 and PD-L1 inhibitor (PD-1 and PD-L1 inhibitor)

Immune-related Adverse Event; Malignant Solid Tumors · PD-1

#PD-1#ADC#Preclinical#인기#항체약물접합체+5
효능 ORR 59%임상시험 59상태 RECRUITING
ADCBiologicstaleStrata OncologyPhase 2

encorafenib + binimetinib (encorafenib + binimetinib)

Cancer; Advanced Solid Tumor · Cancer

#Cancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 66.7%임상시험 48상태 DISCONTINUED
ADCBiologicstaleSichuan Baili Pharmaceutical Co…viaPhase 2

BL-B01D1 (BL-B01D1)

Rare Malignant Neoplasm; Advanced Solid Tumors · Rare Malignant Neoplasm

#RareMalignantNeoplasm#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 44상태 RECRUITING
ADCBiologicCullinan Therapeutics Inc.Deruxtecan-Dlnk Quantificat…Phase 1

Dato-DXd (Datopotamab deruxtecan-dlnk, Datopotamab deruxtecan-dlnk (Dato-DXd))

Advanced Solid Tumor; NSCLC · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 79%임상시험 39상태 RECRUITING
ADCBiologicstaleBeOne MedicinesPhase 1

Anticancer Agents (Anticancer Agents)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 0%임상시험 31상태 RECRUITING
ADCBiologicstaleTaiho Oncology, Inc.Phase 2

Futibatinib (Futibatinib)

Advanced Solid Tumor · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 47.1%임상시험 23상태 RECRUITING

1 / 9 페이지

← 이전다음 →